Affiliation:
1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Abstract
Abstract
Summary:
For too long, assays exposing patient tumor cells to drugs to identify active therapies have been dismissed as ineffective. In this issue of Cancer Discovery, two groups independently demonstrate clinical utility of such functional precision medicine assays in hematologic malignancies.
See related article by Kornauth et al., p. 372.
See related article by Malani et al., p. 388.
Publisher
American Association for Cancer Research (AACR)
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献